Malta - English - Medicines Authority

generics uk limited station close, potters bar, herts, en6 1tl, united kingdom - hydrochlorothiazide, lisinopril - tablet - hydrochlorothiazide 12.5 mg lisinopril 20 mg - agents acting on the renin-angiotensin system

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - aliskiren hemifumarate (unii: c8a0p8g029) (aliskiren - unii:502fwn4q32), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - aliskiren hemifumarate 150 mg - tekturna hct is indicated for the treatment of hypertension. add-on therapy a patient whose blood pressure is not adequately controlled with aliskiren alone or hydrochlorothiazide alone may be switched to combination therapy with tekturna hct. a patient whose blood pressure is controlled with hydrochlorothiazide alone but who experiences hypokalemia may be switched to combination therapy with tekturna hct. a patient who experiences dose-limiting adverse reactions on either component alone may be switched to tekturna hct  containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. replacement therapy tekturna hct may be substituted for the titrated components. initial therapy tekturna hct may be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.  the choice of tekturna hct as initial therapy should be based on an assessment of potential benefits and risks. patients with stage 2 hypertension a

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 25 mg; valsartan, quantity: 160 mg; amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; crospovidone; magnesium stearate; titanium dioxide; hypromellose; purified talc; macrogol 4000; iron oxide yellow - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 25 mg; valsartan, quantity: 320 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; crospovidone; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - exforge hct is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - exforge hct is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - amlodipine besilate; valsartan; hydrochlorothiazide - film-coated tablet - 10 mg/ 160mg/12.5 milligram(s) - angiotensin ii antagonists, other combinations; valsartan, amlodipine and hydrochlorothiazide

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - amlodipine besilate; valsartan; hydrochlorothiazide - film-coated tablet - 10/160/25 milligram(s) - angiotensin ii antagonists, other combinations; valsartan, amlodipine and hydrochlorothiazide

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - amlodipine besilate; valsartan; hydrochlorothiazide - film-coated tablet - 10/320/25 milligram(s) - angiotensin ii antagonists, other combinations; valsartan, amlodipine and hydrochlorothiazide

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - amlodipine besilate; valsartan; hydrochlorothiazide - film-coated tablet - 5 mg/160 mg/12.5 milligram(s) - angiotensin ii antagonists, other combinations; valsartan, amlodipine and hydrochlorothiazide

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - amlodipine besilate; valsartan; hydrochlorothiazide - film-coated tablet - 5 mg/160 mg/25 milligram(s) - angiotensin ii antagonists, other combinations; valsartan, amlodipine and hydrochlorothiazide